
|Articles|March 1, 2007
The wait is over: Lucentis has arrived in Europe
Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5



















